How Cross Border IP Strategy Is Evolving Between the UK, UAE, and India

THE OPPORTUNITY NO ONE IS TALKING ABOUT

Something is shifting. Quietly. Significantly. And most IP professionals have not yet caught up.

Three jurisdictions are converging. The United Kingdom. The United Arab Emirates. India. Each has overhauled its trade frameworks in the past three years. Each is rewriting the rules of how intellectual property moves across borders. And for businesses caught between these three markets, the old playbook no longer works.

This is not a theoretical conversation. It is a practical one. If you are a UK firm advising a client with manufacturing in India, or a UAE based founder scaling a tech product into South Asia, or an Indian company listing in London, your IP strategy must now account for a new reality.

That reality has a name. It is convergence.

THE UK INDIA CORRIDOR: CETA CHANGES EVERYTHING

On 24 July 2025, India and the United Kingdom signed the Comprehensive Economic and Trade Agreement. The IP chapter alone runs 52 pages. It covers patents. Trademarks. Designs. Copyright. Geographical indications. Trade secrets. And enforcement.

That is not a minor annex. That is a full blown IP treaty embedded within a trade deal.

The UK Government has stated that the agreement will lead to improved patent procedures in India. Enhanced transparency. Greater legal certainty. For UK firms accustomed to working with Indian counterparts on an ad hoc basis, CETA now provides a structural framework.

What matters most is what the agreement does not do. It does not import the TRIPS plus provisions that the 2022 leaked draft had threatened. Section 3(d) of the Indian Patents Act, which prevents patent evergreening, stands untouched. The Supreme Court of India upheld the validity and purpose of Section 3(d) in Novartis AG v. Union of India (2013) 6 SCC 1, holding that the beta crystalline form of imatinib mesylate did not demonstrate enhanced therapeutic efficacy. That ruling remains the lodestar. CETA does not disturb it.

India retains the right to grant compulsory licences. Pre grant oppositions survive, though the 2024 Patent Rules amendments have introduced procedural changes that deserve close attention.

The real shift is in cooperation. CETA establishes a Working Group on Intellectual Property Rights under Article 13.15. It mandates patent cooperation and work sharing between the UK Intellectual Property Office and the Indian Patent Office. It requires both sides to simplify and streamline patent examination procedures. The agreement also mandates that both parties make their IP laws, regulations, and administrative rulings publicly available online. This is a transparency commitment that will materially benefit foreign filers.

For foreign counsel advising UK clients with Indian filings, this is actionable intelligence. Shared examination work means faster prosecution. It means citing UK search reports in Indian proceedings may carry greater weight. It means a more predictable timeline.

At Vera Lex, we have already begun structuring dual filing strategies for UK India clients that account for CETA's cooperation mechanisms. The early movers will benefit the most.

THE UAE INDIA CORRIDOR: TRADE, TRUST, AND IP INFRASTRUCTURE

The India UAE relationship is accelerating faster than most people realise.

Bilateral trade hit USD 100 billion in FY 2024 2025. That is not a projection. That is a fact. During the visit of His Highness Sheikh Mohamed bin Zayed Al Nahyan to India on 19 January 2026, both governments set a target to double that figure to USD 200 billion by 2032. The Comprehensive Economic Partnership Agreement signed in 2022 provides the framework. It includes a dedicated intellectual property chapter. Article 11.7 requires national treatment for IP holders from both countries. Article 11.9 mandates transparency in IP laws and decisions. The agreement reinforces TRIPS obligations while preserving domestic flexibilities.

But the real story is infrastructure.

Bharat Mart in Dubai's Jebel Ali Free Zone will house 1,500 showrooms across 2.7 million square feet. Indian companies will display, store, and distribute products to the Middle East and Africa from that hub. Every one of those products will carry trademarks. Many will carry patents. Some will carry registered designs.

Who protects that IP across borders? Who files the UAE trademark before the Dubai launch? Who handles the Indian registration that underpins the export? Who enforces when a counterfeit appears in Sharjah or Ras Al Khaimah?

This is the operational gap that firms like Vera Lex are built to fill.

ENFORCEMENT: WHERE STRATEGY MEETS REALITY

A right without a remedy is no right at all. Cross border IP strategy must end with enforcement or it is just paperwork.

India designated the UAE as a reciprocating territory under Section 44A of the Code of Civil Procedure. This means a final civil judgment from any UAE court, including the DIFC Courts and the ADGM Courts, can be directly enforced in India. No fresh suit required. The limitation period for enforcement extends to 12 years under the Indian Limitation Act, 1963. That is a significant window.

In February 2026, the Andhra Pradesh High Court affirmed this position in Transcom DMCC v. the Respondent (CRP Nos. 1206 and 1212 of 2025). The Court allowed enforcement of a DIFC decree, emphasising that substantive justice must prevail over procedural technicalities. The ruling reinforced India's pro enforcement stance in cross border matters and strengthened commercial confidence in the recognition of foreign judgments.

The practical implications are significant. Consider the recent Delhi High Court decision in Communication Components Antenna Inc. v. Ace Technologies Corp. (CS(COMM) 2025, order dated 1 July 2025). Justice Saurabh Banerjee directed the Korean defendant to deposit INR 290 crore as interim security in a patent infringement suit. The total amount ordered to date stands at INR 365 crore. The Court reasoned that Ace Technologies, a foreign entity with no attachable Indian assets and incorporated in a non reciprocating territory (South Korea), posed a genuine risk of rendering any future decree unenforceable. This is perhaps the largest pre decree deposit ever mandated in Indian IP litigation.

The contrast with the UAE is instructive. Because the UAE is a reciprocating territory, UAE based defendants do not face the same enforcement vacuum. A judgment creditor can proceed directly to execution in India. This makes the India UAE corridor structurally more efficient for cross border IP disputes than many other bilateral relationships.

On the UK side, CETA's enforcement chapter requires both parties to provide effective IP enforcement remedies. Expeditious action against infringement. Deterrent remedies. Judicial measures to preserve evidence. These obligations, read alongside the Delhi High Court's increasingly muscular interim relief jurisprudence (see Nokia Technologies Oy v. Guangdong Oppo Mobile Telecommunications Corp., FAO(OS)(COMM) 321/2022 in CS(COMM) 303/2021, decided 3 July 2023, where the Division Bench directed pro tem security deposits based on 23% of the last paid licence amount and the Supreme Court later dismissed Oppo's challenge), will shape how IP disputes between UK and Indian parties are litigated going forward.

At Vera Lex, we advise clients to think about enforcement before they file. The jurisdiction you choose today determines the remedy you have tomorrow.

THE DIFC AND ADGM ADVANTAGE: COMMON LAW IN THE MIDDLE EAST

Here is something that surprises many Indian and UK practitioners. The DIFC and ADGM are common law jurisdictions. They operate in English. They follow binding precedent.

For Indian counsel accustomed to adversarial proceedings and English language courts, this is familiar territory. For UK solicitors advising clients in the Gulf, these courts offer a bridge between English law principles and UAE commercial reality.

The DIFC Courts have developed a sophisticated enforcement and supportive jurisdiction under Dubai Law No. 2 of 2025. In Carmon Reestrutura v. Cuenda [2024] DIFC CA 003, the DIFC Court of Appeal confirmed free standing jurisdiction to grant worldwide freezing orders in support of foreign proceedings. This was reinforced in Trafigura PTE Ltd v. Prateek Gupta [2025] CA 001, where the Court of Appeal held that Article 15(4) of the New Court Law provides jurisdiction to grant interim measures wherever the foreign proceedings could result in a judgment capable of recognition in the DIFC. In the more recent Oran & Oaken v. Oved [2025] CA 004, the Court clarified that this jurisdiction rests on the enforcement principle, not on a free-standing power to act as a universal policeman.

But there is a caveat. The Conflicts of Jurisdiction Tribunal remains a strategic constraint. In Application No. 002/2025, the CJT found that parallel onshore Dubai proceedings took priority over DIFC enforcement proceedings. Enforcement strategies involving the DIFC must account for onshore courts from the outset.

This is exactly the kind of nuanced, multi-jurisdictional thinking that a cross-border IP practice demands. You cannot advise in silos. You must see the full picture.

PATENT LITIGATION IN INDIA: THE COURTS MEAN BUSINESS

Indian courts are no longer cautious on IP. They are assertive. The Delhi High Court's IP Division has emerged as one of the busiest and most sophisticated patent courts in the world.

Consider Philips v. M. Bathla & Ors. (CS(COMM) 533/2018, decided on 13 October 2025) after a 21 year dispute. This was India's first reported finding of non-infringement in a Standard Essential Patent case. The Court applied a strict claim to product mapping standard, relying on the Delhi High Court Rules Governing Patent Suits, 2022 and the CRI Guidelines, 2025. Philips' evidence was found deficient because it focused on functional outcomes rather than demonstrating how the defendants' systems implemented the entire claimed architecture. The Court also held that private negotiations cannot substitute formal proof of SEP essentiality under Indian evidence law.

In Conqueror v. Xiaomi (2025:DHC:5233), the Delhi High Court reinforced that to prove infringement, all essential elements of the claimed invention must be found in the infringing device. Functional similarity alone is insufficient.

On jurisdiction, Helsinn Healthcare SA v. AET Laboratories (2025:DHC:8655) clarified that mere accessibility of a foreign website in India does not confer territorial jurisdiction on the Delhi High Court. The Court dismissed the quia timet action, holding that listing a product as under development and filing a post grant opposition are insufficient to establish a credible threat of imminent infringement.

And cross border discovery is evolving. In Softgel Healthcare Pvt. Ltd. v. Pfizer Inc. (November 2025, Madras High Court Division Bench), the Court refused to execute Letters Rogatory from a US federal court in Delaware. Pfizer sought manufacturing records from an Indian API supplier. The Court applied Article 3 of the Hague Evidence Convention (specificity), Article 12(b) (sovereignty, noting that Pfizer's Indian patent application had been refused), and Article 23 (prohibited pre-trial discovery). India's Supreme Court has taken up the appeal and directed the Union of India to join as a party. The outcome could reshape how foreign discovery requests are processed in India.

For foreign counsel, the message is clear. India's patent courts are rigorous, technically sophisticated, and increasingly willing to assert their own doctrinal positions. You need Indian counsel who understand this landscape from the inside.

PHARMA AND LIFE SCIENCES: THE MOST SENSITIVE CORRIDOR

The UK India CETA will be tested hardest in pharmaceuticals.

India is the pharmacy of the world. It supplies over 60 percent of global vaccine demand and a substantial share of generic medicines. The UK is a leading innovator in life sciences. Between them lies a delicate balance of patent protection and affordable access.

CETA affirms the Doha Declaration on TRIPS and Public Health. India retains the right to issue compulsory licences. Section 3(d) remains intact. The Supreme Court's reasoning in Novartis that therapeutic efficacy must be enhanced, not merely bioavailability or stability, continues to govern patent examination and opposition practice.

Indian courts have also pushed back firmly on evergreening strategies. In the Dapagliflozin litigation, both the Delhi High Court and the Supreme Court largely rejected AstraZeneca's plea for an injunction. The UK Court of Appeal later revoked the contested patent for lack of plausibility. In the Linagliptin case, the Delhi High Court ruled in January 2025 that a challenge to patent extension through successive filings is valid and carries no time limit.

Yet the agreement also introduces provisions on voluntary licensing preferences and patent working disclosures that deserve careful monitoring. The 2024 Patent Rules amendments, which introduced an additional tier in pre grant opposition and increased filing fees, are part of the same evolving landscape.

Vera Lex works with international pharmaceutical clients and their counsel to map claim charts, anticipation analyses, and prosecution strategies across Indian and foreign patent offices. We understand both the statute and the strategy.

TECHNOLOGY AND STARTUPS: THE FAST-GROWING FRONTIER

The India UAE technology corridor is exploding. Both governments agreed in January 2026 to collaborate on AI infrastructure. A supercomputing cluster in India, jointly built by C DAC and G42 of the UAE, will serve the AI India Mission.

Digital embassies between India and the UAE are being explored. Data centre collaborations are on the table. The Virtual Trade Corridor and the MAITRI platform already connect customs systems between the two countries.

For technology startups, this means the IP pipeline must be built before the product ships. A UAE based AI startup using Indian engineering talent must secure its trade secrets before the first sprint. An Indian SaaS company entering the Gulf must register its trademarks in the UAE before the marketing campaign launches.

The India UK CETA also impacts technology businesses. The agreement covers trade secrets. It mandates protection for encrypted information. It addresses digital copyright enforcement. For UK based tech companies with Indian development teams, these provisions create new obligations and new protections.

At Vera Lex, we advise founders and in house teams to build IP into the product roadmap. Not as an afterthought. As a foundation.

WHY INDIA NEEDS TO BE ON YOUR MAP

India granted over 100,000 patents in the last year. Patent filings have shown double digit growth for six consecutive years. Delhi High Court's IP division handles more patent and trademark cases than most international forums. The Commercial Courts Act of 2015 has compressed timelines and improved judicial efficiency.

India is not a jurisdiction to approach with caution. It is a jurisdiction to approach with strategy.

The Indian IP regime is robust, nuanced, and increasingly aligned with international best practice. But it retains its own character. Section 3(d). Pre grant opposition. Compulsory licensing. Patent working requirements. These are features, not bugs. They reflect a legal system that balances innovation incentives with public interest. The Delhi High Court Rules Governing Patent Suits, 2022 have codified rigorous requirements for claim mapping and technical evidence. The CRI Guidelines, 2025 are shaping how computer related inventions are examined. The courts are applying these standards with precision, as Philips v. Bathla and Conqueror v. Xiaomi demonstrate.

For foreign counsel seeking an Indian partner, the critical question is competence. Not just in filing. In strategy. In litigation. In understanding how Indian courts think and how Indian examiners decide.

Vera Lex was built for this. We are India based. We are internationally fluent. We work with UK and UAE counterparties and their counsel on cross border mandates with the same rigour they expect from firms in London or Dubai.

THE VERA LEX APPROACH

We do not try to be everything to everyone. We are a niche IP practice. Patents. Trademarks. Designs. Plant variety rights. Layout of integrated circuits. Arbitration. That is our universe.

What sets us apart is range within that niche. We draft patent specifications with engineering precision. We argue oppositions with courtroom intensity. We structure multi-jurisdictional filing strategies with the awareness that what happens in one office affects outcomes in another.

Our clients include international law firms who need reliable India execution. In house teams who need a strategic partner rather than a filing agent. And founders who need someone who speaks both the language of innovation and the language of law.

We are comfortable with UK counsel on a joint patent prosecution. We are comfortable with UAE counterparties on a trademark enforcement action. We are comfortable at the intersection of jurisdictions, where the real complexity lives.

WHAT COMES NEXT

The convergence of UK, UAE, and Indian IP frameworks is not a one-time event. It is an ongoing process. CETA is not yet in force. Both countries must complete domestic ratification. The CEPA's IP provisions will evolve as bilateral trade scales. The DIFC and ADGM courts will continue to develop their IP jurisprudence.

The firms and businesses that position themselves now will have a structural advantage. They will have the relationships. They will have the precedents. They will have the strategy.

The bridge is being built. The question is whether you are walking across it.

Key Case Law Referenced

1. Novartis AG v. Union of India (2013) 6 SCC 1 [Supreme Court of India]

2. Transcom DMCC v. Respondent, CRP Nos. 1206 & 1212 of 2025 [Andhra Pradesh High Court, 2026]

3. Communication Components Antenna Inc. v. Ace Technologies Corp., order dated 1 July 2025 [Delhi High Court]

4. Nokia Technologies Oy v. Guangdong Oppo Mobile Telecommunications Corp., FAO(OS)(COMM) 321/2022 in CS(COMM) 303/2021, decided 3 July 2023 [Delhi High Court, Division Bench]

5. Philips v. M. Bathla & Ors., CS(COMM) 533/2018, decided 13 October 2025 [Delhi High Court]

6. Conqueror v. Xiaomi 2025:DHC:5233 [Delhi High Court]

7. Helsinn Healthcare SA v. AET Laboratories 2025:DHC:8655 [Delhi High Court]

8. Softgel Healthcare Pvt. Ltd. v. Pfizer Inc., November 2025 [Madras High Court, Division Bench]

9. Carmon Reestrutura v. Cuenda [2024] DIFC CA 003 [DIFC Court of Appeal]

10. Trafigura PTE Ltd v. Prateek Gupta [2025] CA 001 [DIFC Court of Appeal]

11. Oran & Oaken v. Oved [2025] CA 004 [DIFC Court of Appeal]

Disclaimer: This article is intended for informational purposes only and does not constitute legal advice. The views expressed are those of the author. Readers should seek independent legal counsel for specific matters.